Form 4 for GILD Gilead Sciences
Accepted 2025-02-03 00:00:00 ET · period of report 2025-01-31 · accession 0001127602-25-002821 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-03 | 2025-01-31 | GILD | Dickinson Andrew D | CFO | M - OptEx | $67.52 | +142.2K | 227.9K | +166% | +$9.60M |
| D | 2025-02-03 | 2025-01-31 | GILD | Dickinson Andrew D | CFO | S - Sale+OE | $97.22 | -142.2K | 129.9K | -52% | -$13.82M |
| DM | 2025-02-03 | 2025-01-31 | GILD | Dickinson Andrew D | CFO | M - OptEx | $0.00 | -142.2K | 104.7K | -58% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-31 | M | A | 26,170 | $57.92 | 156,043 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-31 | S | D | 142,180 | $97.22 | 129,873 | D | — | — | (F2) Sales prices reported for the transactions reported here range from $97.22 to $97.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| 3 | Common | Common Stock | 2025-01-31 | M | A | 44,160 | $65.38 | 273,053 | D | — | — | |
| 4 | Common | Common Stock | 2025-01-31 | M | A | 71,850 | $72.34 | 227,893 | D | — | — | |
| 5 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-01-31 | M | D | 71,850 | $0.00 | 0 | D | $72.34 · — to 2030-03-10 | 71,850 Common Stock | (F3) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 6 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-01-31 | M | D | 44,160 | $0.00 | 0 | D | $65.38 · — to 2029-11-10 | 44,160 Common Stock | (F3) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 7 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-01-31 | M | D | 26,170 | $0.00 | 104,690 | D | $57.92 · — to 2032-03-10 | 26,170 Common Stock | (F3) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |